<DOC>
	<DOCNO>NCT02373072</DOCNO>
	<brief_summary>This study two sequential cohort , three treatment period . Single dose PF-06649751 test study , start low dose escalate dose project current limit drug concentration . Each cohort aim achieve approximately 9 completers . Primary endpoint safety tolerability , secondary endpoint MDS-UPDRS part III .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics PF-06649751 Subjects With Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Trimethobenzamide</mesh_term>
	<criteria>LDOPAresponsiveness Hoehn &amp; Yahr Stage IIIII inclusive Experiencing motor fluctuation Stable daily dose LDOPA least 300 mg Females nonchildbearing potential male subject History troublesome dyskinesia History surgical intervention Parkinson 's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pakinson 's Disease , Movement Disorders</keyword>
</DOC>